Literature DB >> 15567626

The diagnostic randomized clinical trial is the best solution for management issues in critical limb ischemia.

Jurgen C de Graaff1, Dirk Th Ubbink, Jan G P Tijssen, Dink A Legemate.   

Abstract

OBJECTIVE: The value of a new diagnostic test is usually established by analyzing its accuracy in relation to a reference standard. Here we describe a potentially better model of diagnostic research, namely, a diagnostic randomized clinical trial (D-RCT), and discuss its pros and cons using management of critical limb ischemia as an example. STUDY DESIGN AND
SETTING: Patients clinically suspected of critical limb ischemia are randomized either for the conventional management strategy (treating physician determines the diagnostic and therapeutic strategy on clinical judgment and ankle pressure) or new strategy (transcutaneous oxygen and toe pressure determine the diagnostic and therapeutic strategy). The effect of the diagnostic work-up on the diagnostic and therapeutic process and clinical outcome will be evaluated.
RESULTS: A D-RCT is suited when a true reference standard is lacking. It is the best available research method to control for confounding and bias, and it also incorporates the total effect (interpretation and side effects) on clinical outcome. The D-RCT has some disadvantages, however, as to the power and size of the trial and the influence of treatment on the outcome parameter.
CONCLUSIONS: A D-RCT can provide valuable information as to the evaluation of diagnostic tests.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15567626     DOI: 10.1016/j.jclinepi.2004.02.020

Source DB:  PubMed          Journal:  J Clin Epidemiol        ISSN: 0895-4356            Impact factor:   6.437


  2 in total

1.  Efficiency of study designs in diagnostic randomized clinical trials.

Authors:  Bo Lu; Constantine Gatsonis
Journal:  Stat Med       Date:  2012-10-15       Impact factor: 2.373

Review 2.  Statistical controversies in clinical research: prognostic gene signatures are not (yet) useful in clinical practice.

Authors:  S Michiels; N Ternès; F Rotolo
Journal:  Ann Oncol       Date:  2016-09-15       Impact factor: 32.976

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.